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Abstract
The underglycosylated mucin 1 tumor antigen (uMUC1) is a biomarker that forecasts the 
progression of adenocarcinomas. In this study, we evaluated the utility of a dual-modality 
molecular imaging approach based on targeting uMUC1 for monitoring chemotherapeutic 
response in a transgenic murine model of pancreatic cancer (KCM triple transgenic mice). An 
uMUC1-specific contrast agent (MN-EPPT) was synthesized for use with magnetic resonance 
imaging (MRI) and fluorescence optical imaging. It consisted of dextran-coated iron oxide 
nanoparticles conjugated to the near infrared fluorescent dye Cy5.5 and to a uMUC1-specific 
peptide (EPPT). KCM triple transgenic mice were given gemcitabine as chemotherapy while 
control animals received saline injections following the same schedule. Changes in uMUC1 levels 
following chemotherapy were monitored using T2-weighted MRI and optical imaging before and 
24 hr after injection of the MN-EPPT. uMUC1 expression in tumors from both groups was 
evaluated by histology and qRT-PCR. We observed that the average delta-T2 in the gemcitabine-
treated group was significantly reduced compared to the control group indicating lower 
accumulation of MN-EPPT, and correspondingly, a lower level of uMUC1 expression. In vivo 
optical imaging confirmed the MRI findings. Fluorescence microscopy of pancreatic tumor 
sections showed a lower level of uMUC1 expression in the gemcitabine-treated group compared to 
the control, which was confirmed by qRT-PCR. Our data proved that changes in uMUC1 
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expression after gemcitabine chemotherapy could be evaluated using MN-EPPT-enhanced in vivo 
MR and optical imaging. These results suggest that the uMUC1-targeted imaging approach could 
provide a useful tool for the predictive assessment of therapeutic response.
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nanoparticles
It is becoming clear that, in the course of therapeutic intervention, cancer cells undergo 
specific molecular transformations long before there is a detectable change in tumor 
morphology or physiology. The ability to detect and analyze the response to therapy at these 
earliest stages of molecular dysregulation, before any overt physiologic symptoms have 
developed, would permit much more adequate therapeutic intervention and would represent 
an additional step in the direction of transforming cancer into a curable disease. The 
conception of molecularly targeted diagnostic approaches would be very valuable toward 
this goal because the ability to predict an individual patient’s response to therapy would 
make therapeutic intervention much more effective and efficient. Such approaches would 
move us closer to the realization of precision medicine in its truest form.
Our search for biomarkers that forecast the progression of adenocarcinoma identified the 
underglycosylated mucin 1 tumor antigen (uMUC1) as a potential candidate. uMUC1 is 
overexpressed and underglycosylated on over 50% of human cancers. Its abundance appears 
to be tightly linked to tumor progression from premalignancy to advanced malignancy, as 
well as to tumor response to chemotherapy.–
The uMUC1 biomarker is highly clinically relevant. In our earlier studies, analysis of 
uMUC1 gene expression and protein abundance in human biopsy samples from breast 
cancer patients revealed a marked upregulation of the antigen in the adjacent normal tissues 
of all patients relative to tissues from women with no cancer history. This altered expression 
was accompanied by post-translational modifications characteristic of oncogenic 
transformation, e.g., basolateral glandular distribution and cytosolic cellular localization. 
These molecular abnormalities in seemingly “normal” tissue, as defined by standard 
histopathology, indicate that uMUC1 is altered very early in the process of breast 
carcinogenesis and could serve as a predictive biomarker of cancer progression.
It is highly desirable to develop a noninvasive technique to image the changes of uMUC1 
expression., To probe for uMUC1 dysregulation using noninvasive imaging, we have 
previously designed and synthesized a contrast agent (MN-EPPT) that consists of iron oxide 
nanoparticles (MN, detectable by magnetic resonance imaging, MRI) conjugated to peptides 
(EPPT), specific for uMUC1. We have shown that MN-EPPT accumulation in tumors 
mirrors the abundance of uMUC1 and is suitable for the tracking of change in tumor size 
following chemotherapy in orthotopic murine models of pancreatic and breast cancer.,
More importantly, we have developed a method for the quantitative assessment of uMUC1 
expression in breast tumors using noninvasive MRI. Specifically, we have shown that 
Wang et al. Page 2













treatment with doxorubicin in an orthotopic mouse model of breast cancer led to 
downregulation of the uMUC1 antigen in the tumors. Ultimately, we provided proof-of-
principle that MN-EPPT-enhanced MRI and optical imaging could detect these changes in 
uMUC1 expression in vivo, establishing a molecular biomarker of chemotherapeutic 
response.
Our further investigation into uMUC1 biology using noninvasive MRI in a transgenic mouse 
model of breast cancer revealed that this antigen is already altered in the premalignant stage.
This indicated that targeting uMUC1 with MN-EPPT could be used for monitoring 
premalignant transformation in the mammary fat pad. Our noninvasive approach was also 
valuable for detecting changes in uMUC1 expression during chemotherapy with doxorubicin 
in this transgenic model, which caused uMUC1 downregulation.
As uMUC1 expression has global relevance in adenocarcinomas including pancreatic cancer,
this study focused on applying our imaging approach to pancreatic cancer, as it has the 
lowest survival rate among all common cancers. We utilized a genetically engineered mouse 
model that spontaneously induced human uMUC1-positive pancreatic cancer,, and evaluated 
changes in uMUC1 expression in response to gemcitabine chemotherapy using MN-EPPT-
enhanced MRI and correlative optical imaging. Our results show that assessment of 
therapeutic response based on uMUC1 downregulation is not restricted to breast cancer,, but 
may be indicative of a global early response of adenocarcinoma cells to proapoptotic 
triggers. Finally, these new results suggest that the described imaging approach could 
provide a useful tool for the predictive assessment of therapeutic response.
 Material and Methods
 Animals and chemotherapy
All animal experiments were performed in compliance with institutional guidelines and 
approved by the Massachusetts General Hospital (MGH) and University of North Carolina 
Institutional Animal Care and Use Committees. To generate a human uMUC1-expressing 
mouse model of pancreatic cancer, first KC mice were generated on the C57BL/6 
background by mating P48-Cre with LSL-KRASG12D mice. They were further mated to 
MUC1.Tg mice to generate KCM mice. Studies were initiated when the animals had an 
average age of 24.5 weeks (treated experimental, n = 4) and 23 weeks (nontreated controls, n 
= 4). The experimental mice were given treatment (gemcitabine, 20 mg/kg. i.p.) twice 
weekly for 10 weeks. The control mice received saline IP injections of the same amount at 
the same time (Table 1).
 MN-EPPT synthesis
Nine grams of Dextan-T10 (Pharmacosmos, Holbaek, Denmark) was dissolved in 30 ml of 
double-distilled water and stirred in a round bottom flask on ice. FeCl3 6H2O (0.65 g, 
Sigma-Aldrich, St. Louis, MO) was added while flushing Ar gas into the reaction mixture 
for an hour. FeCl2·4H2O (0.4 g, Sigma-Aldrich, St. Louis, MO) was added into the mixture 
and then 15 ml of concentrated cold NH4OH (~28%, Sigma-Aldrich, St. Louis, MO) was 
added dropwise to the stirring mixture. The temperature was increased to 85°C for an hour 
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to induce the formation of a nanoparticulate colloidal mixture, cooled to room temperature 
and concentrated to 20 ml using Amicon Ultra centrifugal units (MWCO 30 kDa; Millipore, 
Billerica, MA). The resulting 20 ml dextran-coated magnetic nanoparticles (MN) were 
crosslinked and aminated with the subsequent addition of 35 ml of 5 M NaOH, 14 ml of 
concentrated epichlorohydrin (8 h, Sigma-Aldrich, St. Louis, MO) and 60 ml of 
concentrated NH4OH. The nanoparticle solution was purified using a dialysis bag (MWCO 
14 kDa) against water and 20 mM citrate buffer (pH 8.0) and then concentrated to 20 ml by 
Amicon Ultra centrifugal unit (EMD Millipore, Billerica, MA). The nanoparticle 
concentration was determined by iron assay, and the size of the nanoparticles was 
determined by dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments, Malvern, 
UK).
Cy5.5 monoreactive NHS ester (1 mg, GE Healthcare, Piscataway, NJ) was dissolved in 100 
μl of anhydrous DMSO and incubated with MN (10 mg Fe) in 20 mM citrate buffer (pH 8.0) 
overnight. The nanoparticles were purified using Sephadex PD-10 column (GE Healthcare, 
Piscataway, NJ) with PBS eluent. The number of Cy5.5 molecules per nanoparticle was 
determined to be four Cy5.5 molecules per MN by spectrophotometry. Cy5.5-labeled MN 
(MN-Cy5.5) were loaded with heterobifunctional crosslinkers, N-γ-maleimidobutyryl-
oxysuccinimide ester (GMBS, Pierce Biotechnology, Rockford, IL) and conjugated with 
EPPT peptide. Briefly, 2.4 mg (20.7 nmol) of MN-Cy5.5 was reacted with 0.625 mg (100 
equiv) of GMBS in PBS (pH 8.0) overnight at 4°C and subsequently purified on a PD-10 
column. GMBS-MN-Cy5.5 was conjugated with EPPT peptide (96 nmol, 15 equiv), 
modified with a thiol group at its N-terminus (NH2-Cys-(PEG)-Tyr-Cys(acm)-Ala-Arg-Glu-
Pro-Pro-Thr-Arg-Thr-Phe-Ala-Tyr-Trp-Gly-Lys-CONH2) for the selective conjugation with 
maleimide on MN. The amount of EPPT peptide on MN was quantified by BCA protein 
assay (Pierce Biotechnology, Rockford, IL) and iron assay to confirm the loading ratio of 
EPPT peptide/MN/Cy5.5 (8.7/1/2.3).
 Magnetic resonance imaging
In vivo MRI was performed using a 9.4T Bruker horizontal bore scanner equipped with a 
Rat Array MRI CryoProbes coil (Bruker, Billerica, MA). Multi-slice multi-echo T2-
weighted maps of a mouse abdomen were obtained with the following parameters: TR = 
2,000 msec/TE = 8, 16, 24, 32, 40, 48, 56, 64, 72, 80 msec; slice orientation: axial; number 
of averages (NA) = 2, rapid acquisition with relaxation enhancement factor = 8; FOV = 4.0 
cm2, matrix size 128, spatial resolution 312 mm2, slice thickness = 0.5 mm, flip angle = 
180°, resolution read = 0.025 cm/pixel and scan time = 8 min 32 sec. T2 maps were 
collected on weeks 3, 5, 7, 11, 12 and 13 after the beginning of chemotherapy (Fig. 1). 
Image analysis was performed by two independent investigators blinded to sample identity 
(sample size: treated experimental, n = 4 and nontreated controls, n = 4). T2 maps were 
analyzed voxel-by-voxel by fitting the T2 measurements to a standard exponential decay 
curve, defined by the following equation: y = A exp(−t/T2) using MATLAB software 
R2011b (The MathWorks, Inc., Natick, MA). Average T2 times in free-hand selected region 
of interests (ROIs) surrounding the targeted pancreatic sections were calculated using 
ImageJ software 1.50c (NIH, Bethesda, MD). MRI of experimental and control mice was 
performed before (precontrast) and 24 hr after (postcontrast) intravenous injection of the 
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MN-EPPT (15 mg Fe/kg of body weight). Delta-T2 values were calculated as T2 precontrast 
– T2 postcontrast and were used as an indicator of relative MN-EPPT accumulation.
 Epifluorescence optical imaging
Epifluorescence optical imaging was performed on weeks 10, 11, 13 and 26 after the 
beginning of therapy with gemcitabine (Fig. 1). Images from the animals were obtained 24 
hr after intravenous injection of the MN-EPPT probe using an IVIS Spectrum animal 
imaging system (PerkinElmer, Hopkinton, MA) with specific filters for the Cy5.5 dye on the 
MN-EPPT probe. Imaging was performed over the midsection of the body centered on the 
pancreas. Image analysis was conducted using LivingImage 4.2 software (PerkinElmer, 
Hopkinton, MA). To evaluate imaging results, an ROI was drawn around the selected tissue. 
Average fluorescence signal efficiency, which is defined as fluorescence emission 
normalized to the incident excitation intensity (radiance of the subject/illumination 
intensity), was used for quantification. Fluorescence efficiency was used as a measure of 
relative MN-EPPT accumulation.
 qRT-PCR
Total RNA was extracted from frozen pancreatic tissue lysates using the Qiagen RNeasy 
Mini Kit (Qiagen, Valencia, CA). Taq-Man real-time PCR analysis was done using an ABI 
Prism 7700 sequence detection system (PE Applied Biosystems, Foster City, CA). The PCR 
primers and TaqMan probe specific for MUC1 mRNA were designed using Primer express 
software 1.5. Primer and probe sequences were as follows: forward primer, 5′-
ACAGGTTCTGGTCATGCAAGC-3′; reverse primer, 5′-
CTCACAGCATTCTTCTCAGTAGAGCT-3′; TaqMan probe, 5′-FAM-
TGGAGAAAAGGAGACTTCGGCTACCCAGA-TAMRA-3′. Eukaryotic 18S rRNA 
TaqMan PDAR Endogenous Control reagent mixture (PE Applied Biosystems, Foster City, 
CA) was used to amplify 18S rRNA as a housekeeping control gene. At the RT step, 
incubation was done at 48°C for 30 min followed by 958C for 10 min for enzyme 
inactivation. The PCR amplification was run for 40 cycles at 95°C for 15 sec and at 60°C for 
60 sec. Relative expression was calculated using the delta delta CT method. Two different 
pancreatic samples from each animal were analyzed in triplicate.
 Histology
Immunohistochemistry staining was performed on mouse pancreatic frozen sections by 
staining for uMUC1 and co-localizing it with Cy5.5 signal derived from the MN-EPPT 
probe. Sections were stained with hamster monoclonal anti-mucin 1 antibody (MH1, 1:100 
dilution; Pierce/Thermo Fisher, Carlsbad, CA), followed by incubation with corresponding 
FITC-labeled IgG secondary antibody (1:200 dilution; Abcam, Cambridge, MA) and 
counterstained with DAPI (Vectashield; Vector Laboratories, Inc., Burlingame, CA) for cell 
nucleus staining. The fluorescence images were examined using a Nikon Eclipse 50i 
fluorescence microscope (Nikon, Melville, NY), equipped with the necessary filter sets 
(Chroma Technology Corporation, Bellows Falls, VT). Images were acquired using a 
charge-coupled device camera with near infrared sensitivity (SPOT 7.4 Slider RTKE; 
Diagnostic Instruments, Sterling Heights, MI). Investigators blinded to the animal treatments 
evaluated all tissue sections using SPOT 4.0 Advance version software (Diagnostic 
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Instruments, Sterling Heights, MI). For histology comparison, the consecutive tissue 
sections were stained with hematoxylin and eosin (H&E).
 Statistical analysis
Data are expressed as mean ± SD or SEM, where indicated. Statistical comparisons were 
evaluated by repeated-measures ANOVA. A value of p < 0.05 was considered statistically 
significant.
 Results
 MN-EPPT-enhanced molecular MRI permits the monitoring of therapeutic response
We hypothesized that changes in uMUC1 expression in pancreatic lesions after treatment 
with gemcitabine could be detected using MN-EPPT-enhanced in vivo imaging. This 
capability would provide a prognostic biomarker of therapeutic response. As seen in Figure 
1, MRI permitted the stratification of animals based on treatment with gemcitabine. In 
gemcitabine-treated animals, there was a smaller change in T2 (delta-T2) than in nontreated 
animals (p = 0.0008). This indicated lower accumulation of MN-EPPT and, accordingly, 
lower levels of uMUC1 expression in gemcitabine-treated animals, consistent with our 
hypothesis. Importantly, this difference was seen as early as 7 weeks after the beginning of 
therapy at which point the mice were 30 weeks old—an age associated with early/moderate 
disease (pancreatic intraepithelial, PanIN lesions and carcinoma in situ, CIS)., The 
difference persisted after the discontinuation of treatment after week 10. Of note, one of the 
treated mice was classified as a nonresponder because the delta-T2 of its pancreas was 
consistently larger than that in the remaining treated animals starting at week 7 of treatment 
(Fig. 1). This indicated that gemcitabine had no effect on downregulation of uMUC1 in that 
animal. While this animal was clearly an outlier in this study, we chose to present these 
results as they might reflect a clinical situation when a patient does not respond to treatment. 
This may be the result of a more aggressive cell phenotype selected as a result of treatment 
with cytotoxic therapies, causing a higher level of uMUC1. Indeed, tumor aggressiveness 
and proliferation have long been associated with uMUC1 overexpression in cancer cells,,
which could explain the higher delta-T2 in the case of the nonresponder animal.
 MN-EPPT-enhanced molecular optical imaging permits the monitoring of therapeutic 
response
The findings from MRI were confirmed by in vivo epifluorescence optical imaging. This 
independent imaging modality was made possible by the presence of the Cy5.5 dye on the 
MN-EPPT probe. Figure 2 presents images collected at the end of treatment with 
gemcitabine (week 10) and for 2 weeks after the end of treatment. Fluorescence intensity 
associated with the pancreas of the nontreated animals remained visibly higher than in the 
gemcitabine-treated animals. This indicated persistently higher accumulation of MN-EPPT 
and, correspondingly, higher expression levels of uMUC1. Importantly, this difference was 
retained as late as week 26 after the beginning of treatment (Fig. 3). At that point, the 
animals had not been treated with chemotherapy for 13 weeks and were 49 weeks old, an 
age associated with high-grade disease. This observation suggested that the described 
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imaging method could be useful for the long-term monitoring of disease progression, 
possibly providing an avenue for the early detection of recurrence or tumor growth arrest.
In addition, the observed lack of response in one of the treated animals, as demonstrated by 
MRI, was paralleled by fluorescence optical imaging. As shown in Figure 4, the same mouse 
that presented with abnormally large delta-T2 values on MRI (Fig. 1) had high levels of 
fluorescence associated with the pancreas on optical imaging. This manifestation was 
similar to the nontreated controls and visibly different from the treated animals that 
responded to treatment, in which fluorescence intensity was lower (Fig. 4). The agreement 
between MRI and optical imaging indicates that the observed results indeed reflected 
differences in the accumulation of the MN-EPPT probe and that these differences could be 
considered as a surrogate for therapeutic outcome.
 Ex vivo analysis validates the capacity of the MN-EPPT probe to detect changes in 
uMUC1 expression after treatment with gemcitabine
To corroborate the differences in tissue transformation between animals treated with 
gemcitabine and nontreated controls, we performed histopathological analysis of pancreatic 
sections derived from the study animals 26 weeks after the beginning of treatment. The 
prevalent glandular structure in gemcitabine-treated animals was normal (Supporting 
Information Fig. 1). In control, nontreated animals, there was clear evidence of high-grade 
PanIN lesions and CIS, associated with disorganized glandular epithelium. The 
histopathological appearance of the nontreated animals was indistinguishable from that of 
the nonresponder identified through imaging (Supporting Information Fig. 1).
To confirm the specificity of the MN-EPPT probe for uMUC1, we performed ex vivo 
histological immunostaining analysis of pancreatic sections from experimental and control 
animals. Ex vivo histology of pancreata derived from non-treated control animals revealed 
high expression of uMUC1 (as indicated by anti-uMUC1 staining) distributed throughout 
the disorganized glandular epithelium of PanIN lesions. The accumulation of MN-EPPT, 
indicated by the Cy5.5 signal from the probes, mirrored the distribution of uMUC1. By 
contrast, uMUC1 expression in the pancreatic lesions from the experimental group was 
lower and restricted to the apical membrane of the glandular epithelium. In addition, Cy5.5 
signal from the MN-EPPT probe was low and limited to the apical glandular surface in the 
pancreatic tissues of experimental mice (Fig. 5 and Supporting Information Fig. 2). We also 
performed histological analysis of pancreatic sections from the nonresponder mouse 
identified by MRI and optical imaging. As expected (Fig. 5), immunostaining revealed a 
high expression of uMUC1 in the disorganized glandular epithelium and correspondingly 
high accumulation of MN-EPPT (Fig. 5 and Supporting Information Fig. 2). Finally, the 
differential expression of uMUC1 between non-treated and treated animals was confirmed 
by qRT-PCR (Supporting Information Fig. 3), lending further credence to the hypothesis that 
the accumulation of the MN-EPPT probe in these animals reflects uMUC1 expression.
 Discussion
The ability to monitor cancer progression on a molecular level not defined by the presence 
of a palpable tumor mass and before any overt physiologic symptoms have developed would 
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permit early and more adequate therapeutic intervention. This article addresses this need by 
examining the possibility of predictive diagnostics for therapeutic response in a genetically 
engineered mouse model of pancreatic cancer. Specifically, we illustrate the monitoring of 
therapeutic response by detecting the changes in the expression profile of the molecular 
biomarker uMUC1 with a noninvasive imaging approach. By focusing on early disease, i.e., 
the PanIN lesion, we explore a scenario in which these molecular changes precede changes 
in other anatomical and physiologic signs of therapeutic progress.
This study extends our prior work in breast cancer, which demonstrated that treatment with 
doxorubicin resulted in downregulation of the uMUC1 antigen, and that MN-EPPT-
enhanced MRI and optical imaging could detect changes in uMUC1 expression in vivo. By 
broadening the application of this methodology to pancreatic cancer, we move closer to 
establishing the value of uMUC1 as a wide-ranging predictive cancer biomarker. Based on 
our results from our previous and current studies we believe that uMUC1 downregulation is 
not caused by the specific action of doxorubicin or gemcitabine, but manifests itself as a 
generalized response of the tumor cell to a proapoptotic/cytostatic trigger provided by a 
chemotherapeutic drug. Determination of the precise molecular mechanism behind this 
observation, however, is outside the scope of this investigation and will be reported on 
separately.
Progress has already been made in the direction of predictive cancer diagnostics. An 
example includes screening for the BRCA mutation for the assessment of breast cancer risk.
In most cases, however, cancer diagnostics is still focused on early rather than predictive 
detection. With specific regard to noninvasive imaging, a glimpse into the potential of this 
technology can be derived from the development of dynamic MRI techniques, magnetic 
resonance spectroscopy and positron emission tomography. Still, none of these technologies 
probe for specific molecular biomarkers expressed by cells in proportion to their potential 
for malignancy. Consequently, it is this highly specific molecular imaging approach that has 
the potential for capturing the earliest signs of therapeutic response and permitting predictive 
rather than curative therapeutic intervention.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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During treatment, cancer cells often undergo molecular changes long before tumor 
morphology changes. Biomarkers to detect these changes could enhance therapy by 
allowing earlier analysis. In this study in mice, the authors developed a non-invasive 
technique for imaging cellular levels of the tumor antigen uMUC1, which is 
overexpressed in more than 50% of all cancers. They found that uMUC1 expression 
drops when pancreatic cancer begins to respond to therapy. This imaging technique may 
allow the early assessment of tumor response and prognosis.
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MRI of therapeutic response. The animals were imaged by T2-weighted MRI from 3 to 13 
weeks after the beginning of therapy with gemcitabine. Top—representative T2-weighted 
images (images were obtained on week 11 after the beginning of chemotherapy); bottom—
quantitation of pancreas delta-T2 over time. Visible differences in contrast (top) and 
significant differences in delta-T2 (bottom) were apparent as early as 7 weeks after the 
beginning of therapy, except in one treated animal that presented with a high delta-T2 and 
was identified as a nonresponder (p = 0.0008; nontreated n = 4, treated n = 3; one-way 
repeated-measures ANOVA).
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Fluorescence optical imaging of therapeutic progress. The animals were imaged by 
epifluorescence optical imaging 10, 11 and 13 weeks after the beginning of therapy with 
gemcitabine. Visible differences in fluorescence intensity were apparent during the course of 
imaging.
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In vivo and ex vivo optical imaging at the end of the study (week 26 after the beginning of 
therapy with gemcitabine). The visible differences in fluorescence intensity between treated 
and nontreated animals persisted even at that time point, 15 weeks after the end of 
chemotherapy.
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In vivo optical imaging at the end point of therapy with gemcitabine. There were visible 
differences in fluorescence intensity between treated and nontreated animals, with the 
exception of one treated animal, which was classified as a nonresponder.
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Levels of uMUC1 in pancreatic sections of treated or non-treated animals. There was lower 
staining for uMUC1 in the pancreatic tissues of mice treated with gemcitabine relative to the 
control group. Accordingly, the accumulation of MN-EPPT reflected by the Cy 5.5 signal 
was notably decreased compared with the nontreated group. Immunostaining also identified 
the nonresponder, which had a high expression of uMUC1. uMUC1, green; Cy5.5, red; 
DAPI, blue; magnification bar = 30 μm. Consecutive sections were stained with H&E for 
histology correlation.
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